Table 1
| ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
|---|---|---|---|---|---|---|
| BREAST | S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | Y | ALLIANCE | 91 | ||
| CCTG | 8 | |||||
| ECOG-ACRIN | 97 | |||||
| NRG | 208 | |||||
| SWOG | 422 | |||||
| sum | 826 | |||||
| S1706-Breast, Inflammatory, RT +/- Olaparib | Y | ALLIANCE | 6 | |||
| ECOG-ACRIN | 3 | |||||
| NRG | 18 | |||||
| SWOG | 21 | |||||
| sum | 48 | |||||
| CCD | S1415CD-TrACER CSF Standing Order Intervention for FN | 15-APR-20 | N | ECOG-ACRIN | 394 | |
| SWOG | 2733 | |||||
| S1415CD | N | ALLIANCE | 360 | |||
| NRG | 178 | |||||
| sum | 3665 | |||||
| S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 2 | |||
| ECOG-ACRIN | 8 | |||||
| NRG | 6 | |||||
| SWOG | 65 | |||||
| sum | 81 | |||||
| ERLYTX | S1609-Rare Tumor, Comb Nivo/Ipi | Y | ALLIANCE | 97 | ||
| ECOG-ACRIN | 75 | |||||
| NRG | 124 | |||||
| SWOG | 443 | |||||
| sum | 739 | |||||
| GI | S1613-mCRC, Adv/Met, TP vs CETIRI | Y | ALLIANCE | 4 | ||
| ECOG-ACRIN | 3 | |||||
| NRG | 1 | |||||
| SWOG | 25 | |||||
| sum | 33 | |||||
| S1815-Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel | Y | ALLIANCE | 72 | |||
| ECOG-ACRIN | 55 | |||||
| NRG | 25 | |||||
| SWOG | 124 | |||||
| sum | 276 | |||||
| S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | Y | SWOG | 1 | |||
| sum | 1 | |||||
| GU | S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | Y | ALLIANCE | 83 | ||
| ECOG-ACRIN | 75 | |||||
| NRG | 65 | |||||
| SWOG | 538 | |||||
| sum | 761 | |||||
| S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | Y | ALLIANCE | 35 | |||
| ECOG-ACRIN | 10 | |||||
| NRG | 21 | |||||
| SWOG | 149 | |||||
| sum | 215 | |||||
| S1806-Blad, MIBC, ChemoRT +/- Atezolizumab | Y | ALLIANCE | 3 | |||
| ECOG-ACRIN | 10 | |||||
| NRG | 10 | |||||
| SWOG | 52 | |||||
| sum | 75 | |||||
| LEUK | S1318-ALL, Age 65+, Ph±, Blinatumomab | Y | ALLIANCE | 17 | ||
| ECOG-ACRIN | 6 | |||||
| NRG | 2 | |||||
| SWOG | 30 | |||||
| sum | 55 | |||||
| S1712-CML, Chronic Phase, TKI +/- Ruxolitinib | Y | ALLIANCE | 3 | |||
| ECOG-ACRIN | 1 | |||||
| NRG | 2 | |||||
| SWOG | 24 | |||||
| sum | 30 | |||||
| LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 311 | ||
| ECOG-ACRIN | 163 | |||||
| NRG | 145 | |||||
| SWOG | 750 | |||||
| sum | 1369 | |||||
| S1400F-Non-Match: MEDI4736 + Tremelimumab | 24-MAR-20 | N | ALLIANCE | 12 | ||
| ECOG-ACRIN | 6 | |||||
| NRG | 8 | |||||
| SWOG | 41 | |||||
| sum | 67 | |||||
| S1619-Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC | 01-MAY-20 | N | ECOG-ACRIN | 3 | ||
| S1619 | N | ALLIANCE | 1 | |||
| NRG | 1 | |||||
| SWOG | 24 | |||||
| sum | 29 | |||||
| S1701-Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | Y | ALLIANCE | 1 | |||
| SWOG | 6 | |||||
| sum | 7 | |||||
| S1800A-Non-Match: Ramu + Pembro vs SoC | Y | ALLIANCE | 24 | |||
| ECOG-ACRIN | 12 | |||||
| NRG | 12 | |||||
| SWOG | 70 | |||||
| sum | 118 | |||||
| S1827-SCLC, MRI Surveillance +/- PCI | Y | ALLIANCE | 3 | |||
| SWOG | 2 | |||||
| sum | 5 | |||||
| S1900A-LOH and/or BRCA: Rucaparib | Y | ALLIANCE | 9 | |||
| ECOG-ACRIN | 5 | |||||
| NRG | 5 | |||||
| SWOG | 45 | |||||
| sum | 64 | |||||
| S1900B-RET Fusion: Selpercatinib (LOXO-292) | Y | NRG | 2 | |||
| sum | 2 | |||||
| S1900C-STK11: Talazoparib + Avelumab | Y | ALLIANCE | 3 | |||
| ECOG-ACRIN | 1 | |||||
| NRG | 1 | |||||
| SWOG | 12 | |||||
| sum | 17 | |||||
| LYMPH | S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | Y | ALLIANCE | 8 | ||
| ECOG-ACRIN | 4 | |||||
| NRG | 8 | |||||
| SWOG | 28 | |||||
| sum | 48 | |||||
| S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD | Y | ALLIANCE | 13 | |||
| COG | 54 | |||||
| ECOG-ACRIN | 14 | |||||
| NRG | 9 | |||||
| SWOG | 59 | |||||
| sum | 149 | |||||
| MELAN | S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) | Y | SWOG | 36 | ||
| S1512 | Y | NRG | 3 | |||
| sum | 39 | |||||
| S1607-MELAN, Adv, T-VEC, MK-3475 | Y | ECOG-ACRIN | 8 | |||
| NRG | 2 | |||||
| SWOG | 33 | |||||
| sum | 43 | |||||
| S1616-MELAN, Adv, Ipilimumab ± Nivolumab | Y | ALLIANCE | 9 | |||
| ECOG-ACRIN | 7 | |||||
| NRG | 13 | |||||
| SWOG | 64 | |||||
| sum | 93 | |||||
| S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab | Y | ALLIANCE | 13 | |||
| ECOG-ACRIN | 17 | |||||
| NRG | 17 | |||||
| SWOG | 80 | |||||
| sum | 127 | |||||
| MMYEL | S1803-MM, Maintenance, Len vs Len/Dara | Y | ALLIANCE | 25 | ||
| ECOG-ACRIN | 11 | |||||
| NRG | 16 | |||||
| SWOG | 106 | |||||
| sum | 158 | |||||
| PEOLC | S1316-Compar. Effectiv. Trial for MBO | 15-MAY-20 | N | ECOG-ACRIN | 2 | |
| NRG | 62 | |||||
| SWOG | 130 | |||||
| S1316 | N | ALLIANCE | 27 | |||
| sum | 221 | |||||
| S1820-Rectal, Diet modification to manage GI sx | Y | NRG | 2 | |||
| SWOG | 7 | |||||
| sum | 9 | |||||
| PREV | S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac | Y | ALLIANCE | 29 | ||
| ECOG-ACRIN | 20 | |||||
| NRG | 31 | |||||
| SWOG | 198 | |||||
| sum | 278 | |||||
| SURV | S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 28 | ||
| SWOG | 137 | |||||
| S1501 | Y | ALLIANCE | 17 | |||
| NRG | 15 | |||||
| sum | 197 | |||||
| SXQOL | S1614-HBV in Ca Pts, TAF vs SOC | Y | NRG | 1 | ||
| SWOG | 1 | |||||
| sum | 2 | |||||